Pharmaceutical Regulatory InspectionEnforcement Trends pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
Navigating DSCSA Implementation: Key Requirements & 4 New FDA Guidances
By Madeleine Giaquinto, Manager of Regulatory Affairs, Greenleaf Health, Inc.
In its seventh year of implementation, trading partners involved in manufacturing, distributing, and dispensing prescription drugs in the U.S. (Industry) continue to grapple with requirements of the Drug Supply Chain Security Act (DSCSA), working to set up a fully interoperable electronic system for securing and tracing products across Industry sectors by November 2023. The goal of the DSCSA is to produce a system that enhances national pharmaceutical supply chain security; achieving this goal has required two phases of implementation. In the first phase, traceability requirements at the lot level were implemented beginning in 2015. In the second phase, interoperability requirements allowing for product tracing at the package level are scheduled to become effective in November 2023.
Navigating DSCSA Implementation Key Requirements 4 New FDA Guidances pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
FDAnews Announces CBER’s Five-Year Plan: Address the Agency’s New Priorities and Stay Compliant in a Post-COVID-19 World Webinar July 13, 2021
Share Article
Ready to address CBER’s new priorities? Stay compliant: use innovative technologies to streamline supply chains, mitigate product shortages.
WCG FDAnews CBER’s Five-Year Plan:
An FDAnews Webinar
Ready to address CBER’s new priorities? What it takes to stay compliant is changing… and this is how to stay ahead.
One must incorporate advanced manufacturing processes and use machine learning (ML) and artificial intelligence (AI) along with real-world data (RWD) and real-world evidence (RWE). So says the CBER 2021-2025 Strategic Plan. Its goals require incorporating innovative technologies to more quickly develop safe and effective biologics.
FDA s COVID-19 PREPP Initiative Summary Report â Key Takeaways For Manufacturers
By Madeleine Giaquinto, Manager of Regulatory Affairs, Greenleaf Health, Inc.
In January 2021, as one of his last official acts as the Commissioner of the FDA, Stephen Hahn, M.D., published the
FDA COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) Initiative Summary Report.
1 The PREPP report is the culmination of work performed by the FDA’s PREPP Initiative, which launched in April 2020 to examine lessons learned from the agency’s response spanning FDA policies, processes, operations, communications, and intra-agency coordination to the global COVID-19 pandemic.
2 The FDA asked an independent non-government organization to conduct an objective review of its ongoing COVID-19 response and to summarize findings in the PREPP report. To that end, the third-party organization solicited insights from key FDA staff and external stakeholders, collated lessons learned, and suggested 12 p